Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-FR | Version v3-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-02-07 | 2025-01-27 |
| Drug Identification Number | 02141450 | 02141450 |
| Brand name | 20% PROSOL | 20% PROSOL |
| Common or Proper name | 20% Prosol- Sulfite-Free (Amino Acid) | 20% Prosol- Sulfite-Free (Amino Acid) |
| Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
| Ingredients | TYROSINE L-ASPARTIC ACID SERINE GLUTAMIC ACID PROLINE ARGININE GLYCINE ALANINE TRYPTOPHAN DL-METHIONINE THREONINE PHENYLALANINE LEUCINE ISOLEUCINE HISTIDINE LYSINE VALINE | TYROSINE L-ASPARTIC ACID SERINE GLUTAMIC ACID PROLINE ARGININE GLYCINE ALANINE TRYPTOPHAN DL-METHIONINE THREONINE PHENYLALANINE LEUCINE ISOLEUCINE HISTIDINE LYSINE VALINE |
| Strength(s) | 0.05G 0.6G 1.02G 1.02G 1.34G 1.96G 2.06G 2.76G 0.32G 0.76G 0.98G 1G 1.08G 1.08G 1.18G 1.35G 1.44G | 0.05G 0.6G 1.02G 1.02G 1.34G 1.96G 2.06G 2.76G 0.32G 0.76G 0.98G 1G 1.08G 1.08G 1.18G 1.35G 1.44G |
| Dosage form(s) | LIQUID | LIQUID |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 6 ea/ca | 6 ea/ca |
| ATC code | B05BA | B05BA |
| ATC description | I.V. SOLUTIONS | I.V. SOLUTIONS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2025-01-08 | 2025-01-08 |
| Actual start date | 2025-01-08 | 2025-01-08 |
| Estimated end date | 2025-02-03 | 2025-02-03 |
| Actual end date | 2025-02-06 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Indirect substitute: JB6583 TRAVASOL 10% W/O LYTES 3000 ML and JB6584 TRAVASOL 10% W/O LYTES 1000 ML The composition of each product/comparison of the amino acid profiles would need to be shared with end users. | Indirect substitute: JB6583 TRAVASOL 10% W/O LYTES 3000 ML and JB6584 TRAVASOL 10% W/O LYTES 1000 ML The composition of each product/comparison of the amino acid profiles would need to be shared with end users. |
| Health Canada comments |